Drugs / AAV2-BDNF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05040217 | Feb 2022 → Jul 2028 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Mark Tuszynski | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV2-BDNF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05040217 ↗ |
| Target | BDNF | “AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.” NCT05040217 ↗ |